CTMSS

PULSES Boston
2026-06-03 - 2026-06-04
Course Overview
This in-depth training course offers a Certificate of Completion and features lectures and over 3 hours of hands-on training delivered by Clinical TMS Society renowned clinicians, engineers, and researchers, along with special guests. Attendees will receive current, historical, and practical knowledge for treating patients with TMS based on the best available evidence.
The Program Includes:

A review of the clinical studies that serve as the foundation for treatment of TMS for depression, as well as clinically applicable research and current important studies.
Four lectures on the practical administration of TMS for patients, including practice setup to patient dosing, scheduling, and management.
A review of protocols for TMS: high frequency, theta-burst, low frequency, bilateral, alternative brain targets, rescue treatment, and maintenance treatment.
A revised lecture on TMS risks and their prevention and management, including seizure protocol review.
Hands-on training on coil location placement & motor threshold determination with multiple TMS devices.
A review of promising indications beyond depression, including, obsessive compulsive disorder, smoking cessation, migraine, post-traumatic stress disorder, anxiety, and pain.
An extended Q&A Panel with all PULSES faculty and special guests.

MORE DETAILS COMING SOON... Sign up for updates on when CTMSS opens PULSES registration...

Pain Academy Boston
2026-06-04

CTMSS 14th Annual Meeting
2026-06-04 - 2026-06-06

Clinical Outcomes Comparing MST and ECT in Patients with Depression
2026-07-07 20:00 - 21:00 UTC
> >Register Now <<
Speaker: Daniel M. Blumberger, MD, MSc, FRCPC, FCTMSS
This presentation will present data from a large confirmatory efficacy trial of Magnetic Seizure Therapy in unipolar Depression and a smaller trial in patients with Bipolar Depression.
This treatment utilizes transcranial magnetic stimulation to induce a brief seizure with the hope of inducing similar clinical benefit without cognitive adverse effects of ECT.
Key learning objectives include:

Review the background and rationale for studying MST and ECT in the treatment of depression.
Understand the methodology and design of the CREST and CORRECT-BD trials.
Evaluate the efficacy, safety, tolerability, and clinical implications of MST as a potential treatment for TRD.

One CME credit is available. CE Language
Take advantage of our live Q&A session at the conclusion of the webinar.
*Registered attendees will receive access to the on-demand video recording by Friday, July 10, 2026. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar.
When:
USA - July 7, 2026 at 8:00pm ET | 5:00pm PT
UK- July 8, 2026 at 1:00am BST
Australia- July 8, 2026 at 10:00am AEST
Cost:
Member: $25
Trainee Member: FREE
Non-Member: $50
> >Register Now <<
About the Speaker

Daniel M. Blumberger, MD, MSc, FRCPC, FCTMSS

Dr. Blumberger is a Senior Scientist in the Campbell Family Mental Health Research Institute at Centre for Addiction and Mental Health and a subspecialist in geriatric psychiatry. He is the Temerty Chair in Therapeutic Brain Intervention and the Scientific Director of the Temerty Centre for Therapeutic Brain Intervention. He is the Chief of the General Adult Psychiatry and Health Systems Division at CAMH and is a Professor in the Department of Psychiatry at the University of Toronto. He is the Provincial Clinical Lead for Neurostimulation Procedure for Ontario Health.
His primary area of research focuses on clinical intervention trials of neurostimulation and other novel treatments for depression across the lifespan.
He is the principal or co-investigator on multiple clinical trials using different interventional psychiatry modalities including: psilocybin assisted psychotherapy, IV ketamine, electroconvulsive therapy (ECT), magnetic seizure therapy (MST), repetitive transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS).

Autonomic Outflow as a Rapid Read-Out of Brain Stimulation Targets for Anxious Arousal
2026-08-04 20:00 - 21:00 UTC
> >Register Now <<
Speaker: Ryan Webler, MD
Autonomic hyperactivation is a core feature of anxiety-related disorders that is inadequately addressed by current treatment approaches. Localizing autonomic
arousal to a specific brain circuit could inform the development of new treatments.
Here, Dr. Webler presents causal circuit mapping findings showing that focal brain stimulation sites that rapidly modify autonomic arousal map to a convergent brain circuit across stimulation modalities (TMS, DBS, LIFU). In additional independent datasets, modulation of this circuit predicts sustained changes in anxiety-related autonomic hyperactivation. These findings: (1) implicate the autonomic arousal circuit as a potential brain stimulation target for autonomic hyperactivation, and (2) suggest that rapid autonomic arousal changes could potentially serve as a biomarker of sustained autonomic arousal changes.
Key learning objectives include:

Describe how autonomic hyperactivation to anxiogenic stimuli contributes to clinical anxiety, and why it is inadequately addressed by current treatments.
Explain how focal brain stimulation (e.g., TMS, DBS, LIFU) can rapidly modulate autonomic outflow, and how this outflow maps onto a convergent brain circuit for sympathetic arousal.
Evaluate the evidence that the autonomic arousal circuit predicts sustained changes in anxious arousal and identify its potential as a therapeutic target.

One CME credit is available. CE Language
Take advantage of our live Q&A session at the conclusion of the webinar.
*Registered attendees will receive access to the on-demand video recording by Friday, August 7, 2026. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar.
When:
USA - August 4, 2026 at 8:00pm ET | 5:00pm PT
UK- August 5, 2026 at 1:00am BST
Australia- August 5, 2026 at 10:00am AEST
Cost:
Member: $25
Trainee Member: FREE
Non-Member: $50
> >Register Now <<
About the Speaker

Ryan Webler, MD
Dr. Ryan Webler is a postdoctoral research fellow at Harvard Medical School where he uses causal circuit mapping to develop better brain stimulation treatments for anxiety-related disorders. Complementing his research agenda, he is also a postdoctoral clinical fellow at Boston Precision Neurotherapeutics where he implements evidence-based psychotherapeutic protocols to bolster TMS gains.

Transcranial Magnetic Stimulation's Journal Club
2026-08-18 12:00 - 17:00 UTC | Zoom
Transcranial Magnetic Stimulation is the Society's open-access journal and is the first premier journal dedicated to clinical and foundational studies of TMS.
Members of the Research Committee host a quarterly journal club meeting during which published authors of Transcranial Magnetic Stimulation present their research and answer questions from attendees. Participation in the journal club—and access to the journal—is free and open to both Society members and non-members.
Date/Time:

USA - Tuesday, August 18, 2026 at 12:00pm ET
UK - Wednesday, August 18, 2026 at 5pm GMT
Australia - Thursday, August 19, 2026 at 4am AEDT

Zoom Link:
https://us02web.zoom.us/j/81925772026?pwd=[REDACTED]
Webinar ID: 819 2577 2026
Passcode: [REDACTED]
Can't make this date and time? The recording will be available on the CTMSS website.

EEG-guided TMS: the State of the Evidence
2026-09-01 20:00 - 21:00 (America/New_York)
> >Register Now <<
Speaker: Andrew F. Leuchter, MD
Treatments for Major Depressive Disorder (MDD) act at different hierarchical levels of biological complexity, ranging from the individual synapse to the brain as a whole. Evidence suggests that modulation of synchronized electrical activity in brain networks may integrate these different levels of complexity, and may be central to the mechanism of action of repetitive Transcranial Magnetic Stimulation (rTMS). Several lines of research indicate that electroencephalogram (EEG) recording during rTMS can help elucidate the mechanism of action of rTMS treatment. There is emerging evidence that EEG also may be useful in guiding selection of EEG treatment parameters. This presentation will review data on whether EEG guidance of rTMS treatment can improve treatment outcomes for MDD or other neuropsychiatric disorders.
Key learning objectives include:

Discuss the possible role of biomarkers to guide TMS treatment
Understand the rationale for EEG measurement of the effects of EEG treatment
Examine evidence supporting the use of EEG to guide clinical treatment

Take advantage of our live Q&A session at the conclusion of the webinar.
*Registered attendees will receive access to the on-demand video recording by Friday, September 4, 2026. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar.
When:
USA - Sept 1, 2026 at 8:00pm ET | 5:00pm PT
UK- Sept 2, 2026 at 1:00am BST
Australia- Sept 2, 2026 at 10:00am AEST
Cost:
Member: $25
Trainee Member: FREE
Non-Member: $50
> >Register Now <<
About the Speaker

Andrew F. Leuchter, MD
Andrew F. Leuchter, MD, is a Distinguished Professor of Psychiatry and Director of the Neuromodulation Division at UCLA. An expert on the treatment of mood disorders, Dr. Leuchter directs the Transcranial Magnetic Stimulation (TMS) Clinical and Research Service. This is one of the largest academic TMS program in the country and treats patients with depression, OCD, pain, tinnitus, and other neuropsychiatric illness. His research aims to develop novel treatment strategies and predict which treatments are most likely to benefit individual patients.​
Dr. Leuchter has authored over 200 scientific articles on topics including neuromodulation for the treatment of depression, EEG biomarkers to guide treatment of neuropsychiatric illness, and theories of antidepressant action. He teaches internationally on TMS and other neuromodulation methods.

Pain Academy San Diego
2026-10-15

PULSES Providence
2026-10-23 - 2026-10-25
Course Overview
This in-depth training course offers a Certificate of Completion and features lectures and over 3 hours of hands-on training delivered by Clinical TMS Society renowned clinicians, engineers, and researchers, along with special guests. Attendees will receive current, historical, and practical knowledge for treating patients with TMS based on the best available evidence.
The Program Includes:

A review of the clinical studies that serve as the foundation for treatment of TMS for depression, as well as clinically applicable research and current important studies.
Four lectures on the practical administration of TMS for patients, including practice setup to patient dosing, scheduling, and management.
A review of protocols for TMS: high frequency, theta-burst, low frequency, bilateral, alternative brain targets, rescue treatment, and maintenance treatment.
A revised lecture on TMS risks and their prevention and management, including seizure protocol review.
Hands-on training on coil location placement & motor threshold determination with multiple TMS devices.
A review of promising indications beyond depression, including, obsessive compulsive disorder, smoking cessation, migraine, post-traumatic stress disorder, anxiety, and pain.
An extended Q&A Panel with all PULSES faculty and special guests.

Register
